SAREPTA THERAPEUTICS, INC. Research and Development Expense
SAREPTA THERAPEUTICS, INC. (SRPT) reported Research and Development Expense of $207.24 million for the 3-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2021-03-01
- SAREPTA THERAPEUTICS, INC. research and development expense for the quarter ending 2020-12-31 was $207.24M, a 7.13% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. research and development expense for the quarter ending 2020-09-30 was $190.44M, a 42.17% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. research and development expense for the quarter ending 2020-06-30 was $188.52M, a 66.44% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. research and development expense for the quarter ending 2020-03-31 was $136.14M, a 50.35% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. research and development expense for fiscal 2018 was $401.84M, a 141.05% increase from fiscal 2017.
- SAREPTA THERAPEUTICS, INC. research and development expense for fiscal 2017 was $166.71M, a 11.45% decline from fiscal 2016.
- SAREPTA THERAPEUTICS, INC. research and development expense for fiscal 2016 was $188.27M, a 28.61% increase from fiscal 2015.
- SAREPTA THERAPEUTICS, INC. research and development expense for fiscal 2015 was $146.39M, a 55.36% increase from fiscal 2014.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 371 month | Research and Development Expense 374 month | Research and Development Expense 377 month | Research and Development Expense 380 month | Research and Development Expense 383 month | Research and Development Expense 386 month | Research and Development Expense 389 month | Research and Development Expense 392 month | Research and Development Expense 395 month | Research and Development Expense 398 month | Research and Development Expense 401 month | Research and Development Expense 404 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | $207.24M 10-K · filed 2021-03-01 | $397.68M derived: sum of 2 quarters · filed 2021-03-01 | $586.20M derived: sum of 3 quarters · filed 2021-03-01 | $722.34M derived: sum of 4 quarters · filed 2021-03-01 | ||||||||||||
| 2020-09-30 | $190.44M 10-K · filed 2021-03-01 | $378.96M derived: sum of 2 quarters · filed 2021-03-01 | $515.10M derived: sum of 3 quarters · filed 2021-03-01 | $738.25M derived: sum of 4 quarters · filed 2021-03-01 | ||||||||||||
| 2020-06-30 | $188.52M 10-K · filed 2021-03-01 | $324.67M derived: sum of 2 quarters · filed 2021-03-01 | $547.81M derived: sum of 3 quarters · filed 2021-03-01 | $681.76M derived: sum of 4 quarters · filed 2021-03-01 | ||||||||||||
| 2020-03-31 | $136.14M 10-K · filed 2021-03-01 | $359.29M derived: sum of 2 quarters · filed 2021-03-01 | $493.23M derived: sum of 3 quarters · filed 2021-03-01 | $606.50M derived: sum of 4 quarters · filed 2021-03-01 | ||||||||||||
| 2019-12-31 | $223.14M 10-K · filed 2021-03-01 | $357.09M derived: sum of 2 quarters · filed 2021-03-01 | $470.36M derived: sum of 3 quarters · filed 2021-03-01 | $560.91M derived: sum of 4 quarters · filed 2021-03-01 | ||||||||||||
| 2019-09-30 | $133.95M 10-K · filed 2021-03-01 | $247.22M derived: sum of 2 quarters · filed 2021-03-01 | $337.77M derived: sum of 3 quarters · filed 2021-03-01 | $483.98M derived: sum of 4 quarters · filed 2021-03-01 | ||||||||||||
| 2019-06-30 | $113.27M 10-K · filed 2021-03-01 | $203.82M 10-Q · filed 2019-08-07 | $350.03M derived: sum of 3 quarters · filed 2021-03-01 | $436.61M derived: sum of 4 quarters · filed 2021-03-01 | ||||||||||||
| 2019-03-31 | $90.55M 10-K · filed 2021-03-01 | $236.76M derived: sum of 2 quarters · filed 2021-03-01 | $323.34M derived: sum of 3 quarters · filed 2021-03-01 | $446.19M derived: sum of 4 quarters · filed 2021-03-01 | ||||||||||||
| 2018-12-31 | $146.21M 10-K · filed 2020-02-26 | $232.79M derived: sum of 2 quarters · filed 2020-02-26 | $355.64M derived: sum of 3 quarters · filed 2020-02-26 | $401.84M 10-K · filed 2019-02-28 | ||||||||||||
| 2018-09-30 | $86.58M 10-K · filed 2020-02-26 | $209.43M derived: sum of 2 quarters · filed 2020-02-26 | $255.64M 10-Q · filed 2018-10-31 | $300.08M derived: sum of 4 quarters · filed 2020-02-26 | ||||||||||||
| 2018-06-30 | $122.85M 10-K · filed 2020-02-26 | $169.05M 10-Q · filed 2019-08-07 | $213.49M derived: sum of 3 quarters · filed 2020-02-26 | $247.73M derived: sum of 4 quarters · filed 2020-02-26 | ||||||||||||
| 2018-03-31 | $46.20M 10-K · filed 2020-02-26 | $90.64M derived: sum of 2 quarters · filed 2020-02-26 | $124.88M derived: sum of 3 quarters · filed 2020-02-26 | $183.79M derived: sum of 4 quarters · filed 2020-02-26 | ||||||||||||
| 2017-12-31 | $44.44M 10-K · filed 2019-02-28 | $78.68M derived: sum of 2 quarters · filed 2019-02-28 | $137.59M derived: sum of 3 quarters · filed 2019-02-28 | $166.71M 10-K · filed 2019-02-28 | ||||||||||||
| 2017-09-30 | $34.24M 10-K · filed 2019-02-28 | $93.15M derived: sum of 2 quarters · filed 2019-02-28 | $122.27M 10-Q · filed 2018-10-31 | $193.01M derived: sum of 4 quarters · filed 2019-02-28 | ||||||||||||
| 2017-06-30 | $58.91M 10-K · filed 2019-02-28 | $88.03M 10-Q · filed 2018-08-08 | $158.78M derived: sum of 3 quarters · filed 2019-02-28 | $193.13M derived: sum of 4 quarters · filed 2019-02-28 | ||||||||||||
| 2017-03-31 | $29.12M 10-K · filed 2019-02-28 | $99.87M derived: sum of 2 quarters · filed 2019-02-28 | $134.22M derived: sum of 3 quarters · filed 2019-02-28 | $178.56M derived: sum of 4 quarters · filed 2019-02-28 | ||||||||||||
| 2016-12-31 | $70.75M 10-K · filed 2018-03-01 | $105.10M derived: sum of 2 quarters · filed 2018-03-01 | $149.45M derived: sum of 3 quarters · filed 2018-03-01 | $188.27M 10-K · filed 2019-02-28 | ||||||||||||
| 2016-09-30 | $34.35M 10-K · filed 2018-03-01 | $78.70M derived: sum of 2 quarters · filed 2018-03-01 | $117.52M 10-Q · filed 2017-11-01 | $158.90M derived: sum of 4 quarters · filed 2018-03-01 | ||||||||||||
| 2016-06-30 | $44.35M 10-K · filed 2018-03-01 | $83.17M 10-Q · filed 2017-08-03 | $124.55M derived: sum of 3 quarters · filed 2018-03-01 | $161.22M derived: sum of 4 quarters · filed 2018-03-01 | ||||||||||||
| 2016-03-31 | $38.83M 10-K · filed 2018-03-01 | $80.20M derived: sum of 2 quarters · filed 2018-03-01 | $116.88M derived: sum of 3 quarters · filed 2018-03-01 | $146.06M derived: sum of 4 quarters · filed 2018-03-01 | ||||||||||||
| 2015-12-31 | $41.38M 10-K · filed 2017-02-28 | $78.05M derived: sum of 2 quarters · filed 2017-02-28 | $107.23M derived: sum of 3 quarters · filed 2017-02-28 | $146.39M 10-K · filed 2018-03-01 | ||||||||||||
| 2015-09-30 | $36.67M 10-K · filed 2017-02-28 | $65.85M derived: sum of 2 quarters · filed 2017-02-28 | $105.02M 10-Q · filed 2016-11-07 | $135.85M derived: sum of 4 quarters · filed 2017-02-28 | ||||||||||||
| 2015-06-30 | $29.18M 10-K · filed 2017-02-28 | $68.34M 10-Q · filed 2016-08-09 | $99.18M derived: sum of 3 quarters · filed 2017-02-28 | $121.03M derived: sum of 4 quarters · filed 2017-02-28 | ||||||||||||
| 2015-03-31 | $39.16M 10-K · filed 2017-02-28 | $70.00M derived: sum of 2 quarters · filed 2017-02-28 | $91.85M derived: sum of 3 quarters · filed 2017-02-28 | $112.49M derived: sum of 4 quarters · filed 2017-02-28 | ||||||||||||
| 2014-12-31 | $30.83M 10-K · filed 2016-02-25 | $52.68M derived: sum of 2 quarters · filed 2016-02-25 | $73.33M derived: sum of 3 quarters · filed 2016-02-25 | $94.23M 10-K · filed 2017-02-28 | ||||||||||||
| 2014-09-30 | $21.85M 10-K · filed 2016-02-25 | $42.49M derived: sum of 2 quarters · filed 2016-02-25 | $63.40M 10-Q · filed 2015-11-05 | $88.47M derived: sum of 4 quarters · filed 2016-02-25 | ||||||||||||
| 2014-06-30 | $20.64M 10-K · filed 2016-02-25 | $41.55M 10-Q · filed 2015-08-06 | $66.62M derived: sum of 3 quarters · filed 2016-02-25 | $87.71M derived: sum of 4 quarters · filed 2016-02-25 | ||||||||||||
| 2014-03-31 | $20.91M 10-K · filed 2016-02-25 | $45.98M derived: sum of 2 quarters · filed 2016-02-25 | $67.07M derived: sum of 3 quarters · filed 2016-02-25 | $80.05M derived: sum of 4 quarters · filed 2016-02-25 | $479.48M 10-Q · filed 2014-05-08 | |||||||||||
| 2013-12-31 | $25.08M 10-K · filed 2015-02-26 | $46.16M derived: sum of 2 quarters · filed 2015-02-26 | $59.15M derived: sum of 3 quarters · filed 2015-02-26 | $72.91M 10-K · filed 2016-02-25 | $458.58M 10-K · filed 2014-03-03 | |||||||||||
| 2013-09-30 | $21.09M 10-Q · filed 2014-11-06 | $34.07M derived: sum of 2 quarters · filed 2015-02-26 | $47.83M 10-Q · filed 2014-11-06 | $60.67M derived: sum of 4 quarters · filed 2015-02-26 | $433.50M 10-Q · filed 2013-11-12 | |||||||||||
| 2013-06-30 | $12.98M 10-K · filed 2015-02-26 | $26.75M 10-Q · filed 2014-08-07 | $39.58M derived: sum of 3 quarters · filed 2015-02-26 | $50.49M derived: sum of 4 quarters · filed 2015-02-26 | $412.41M 10-Q · filed 2013-08-08 | |||||||||||
| 2013-03-31 | $13.76M 10-K · filed 2015-02-26 | $26.60M derived: sum of 2 quarters · filed 2015-02-26 | $37.51M derived: sum of 3 quarters · filed 2015-02-26 | $51.36M derived: sum of 4 quarters · filed 2015-02-26 | $399.43M 10-Q · filed 2013-05-09 | |||||||||||
| 2012-12-31 | $12.83M 10-K · filed 2014-03-03 | $23.75M derived: sum of 2 quarters · filed 2014-03-03 | $37.60M derived: sum of 3 quarters · filed 2014-03-03 | $52.40M 10-K · filed 2015-02-26 | $385.67M 10-K · filed 2013-03-15 | |||||||||||
| 2012-09-30 | $10.91M 10-K · filed 2014-03-03 | $24.76M derived: sum of 2 quarters · filed 2014-03-03 | $39.57M 10-Q · filed 2013-11-12 | $58.27M derived: sum of 4 quarters · filed 2014-03-03 | $372.83M 10-Q · filed 2012-11-07 | |||||||||||
| 2012-06-30 | $13.85M 10-K · filed 2014-03-03 | $28.65M 10-Q · filed 2013-08-08 | $47.35M derived: sum of 3 quarters · filed 2014-03-03 | $62.97M derived: sum of 4 quarters · filed 2014-03-03 | $361.92M 10-Q · filed 2012-08-07 | |||||||||||
| 2012-03-31 | $14.80M 10-K · filed 2014-03-03 | $33.51M derived: sum of 2 quarters · filed 2014-03-03 | $49.12M derived: sum of 3 quarters · filed 2014-03-03 | $66.87M derived: sum of 4 quarters · filed 2014-03-03 | $348.07M 10-Q · filed 2012-05-10 | |||||||||||
| 2011-12-31 | $18.70M 10-K · filed 2013-03-15 | $34.31M derived: sum of 2 quarters · filed 2013-03-15 | $52.06M derived: sum of 3 quarters · filed 2013-03-15 | $66.86M 10-K · filed 2014-03-03 | $333.27M 10-K · filed 2012-03-13 | |||||||||||
| 2011-09-30 | $15.61M 10-K · filed 2013-03-15 | $33.36M derived: sum of 2 quarters · filed 2013-03-15 | $48.16M 10-Q · filed 2012-11-07 | $62.05M derived: sum of 4 quarters · filed 2013-03-15 | $314.56M 10-Q · filed 2011-11-08 | |||||||||||
| 2011-06-30 | $17.75M 10-K · filed 2013-03-15 | $32.55M 10-Q · filed 2012-08-07 | $46.44M derived: sum of 3 quarters · filed 2013-03-15 | $55.50M derived: sum of 4 quarters · filed 2013-03-15 | $298.95M 10-Q · filed 2011-08-08 | |||||||||||
| 2011-03-31 | $14.80M 10-K · filed 2013-03-15 | $28.69M derived: sum of 2 quarters · filed 2013-03-15 | $37.75M derived: sum of 3 quarters · filed 2013-03-15 | $44.68M derived: sum of 4 quarters · filed 2013-03-15 | ||||||||||||
| 2010-12-31 | $13.89M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $22.95M derived: sum of 2 quarters · filed 2013-03-15 | $29.88M derived: sum of 3 quarters · filed 2013-03-15 | $35.97M 10-K · filed 2013-03-15 | ||||||||||||
| 2010-09-30 | $9.06M 10-Q · filed 2011-11-08 | $15.99M derived: sum of 2 quarters · filed 2011-11-08 | $22.08M 10-Q · filed 2011-11-08 | |||||||||||||
| 2010-06-30 | $6.93M 10-Q · filed 2011-08-08 | $13.02M 10-Q · filed 2011-08-08 | ||||||||||||||
| 2009-12-31 | $24.40M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |